[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.125.253. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
April 9, 2003

Experimental Drugs Take Aim at Obesity

JAMA. 2003;289(14):1763-1764. doi:10.1001/jama.289.14.1763

Five years after the US Food and Drug Administration (FDA) banned the popular weight-loss drug fenfluramine after reports of heart-valve problems, three prescription weight-loss drugs remain on the US market. Just two are approved for long-term use. Phentermine, the first half of the infamous "Phen-Fen" combination, is still approved for short-term use.

In a nation of 60 million obese adults, the drug industry should be hungry to treat the condition. Yet, the Pharmaceutical Research and Manufacturers of America (PhRMA) lists only 11 new antiobesity drugs in clinical trials.

First Page Preview View Large
First page PDF preview
First page PDF preview
×